\-\ Texto\\:\\ \ \(0\)\
\-\ lp\\ \\-\\ csf\\ negative\\ \\ for\\ lymphoma\ \(0\)\
\-\ radiation\\ with\\ chemotherapy\\ to\\ follow\\.\ \(0\)\
\-\ enhancing\\ mass\\ involving\\ the\\ corpus\\ callosum\\ and\\ spreading\\ into\\ both\\ cerebral\\ hemispheres\\.\\ \\ there\\ is\\ a\\ separate\\ component\\ in\\ the\\ frontal\\ horn\\ of\\ the\\ left\\ lateral\\ ventricle\ \(0\)\
\-\ glioblastoma\\ multiforme\\ \\(who\\ grade\\ 4\\ astrocytoma\\)\ \(0\)\
\-\ \\â\\€\\¢\\ lymphoma\ \(6\)\
\-\ \\â\\€\\¢\\ glioma\\ \\(astrocytoma\\)\ \(0\)\
\-\ \\â\\€\\¢\\ abscess\ \(6\)\
\-\ \\â\\€\\¢\\ metastatic\\ disease\ \(13\)\
\-\ 66\\ year\\ old\\ woman\\ with\\ problems\\ ambulating\\.\\ family\\ noted\\ marked\\ change\\ in\\ personality\\ over\\ past\\ 3\\ months\ \(0\)\
\-\ expansile\\ or\\ tumefactive\\ corpus\\ callosum\\ lesions\\ are\\ almost\\ always\\ infiltrating\\ gliomas\\ or\\ primary\\ cns\\ lymphoma\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ callosum\\:\\ 0\\.27349986069346105\ \(0\)\
\-\ corpus\\:\\ 0\\.26472074623177655\ \(0\)\
\-\ lymphoma\\:\\ 0\\.2593966781427617\ \(0\)\
\-\ astrocytoma\\:\\ 0\\.2192002892336219\ \(0\)\
\-\ spreading\\:\\ 0\\.1938988326830133\ \(0\)\
\-\ personality\\:\\ 0\\.18657696605736165\ \(0\)\
\-\ ambulating\\:\\ 0\\.18453977957247947\ \(0\)\
\-\ lp\\:\\ 0\\.1748812966080673\ \(0\)\
\-\ gliomas\\:\\ 0\\.16789653748050773\ \(0\)\
\-\ tumefactive\\:\\ 0\\.16501218145648955\ \(0\)\
\-\ multiforme\\:\\ 0\\.1512940499913487\ \(0\)\
\-\ separate\\:\\ 0\\.14561476901574757\ \(0\)\
\-\ glioblastoma\\:\\ 0\\.14478022723376383\ \(0\)\
\-\ horn\\:\\ 0\\.1431890063721226\ \(0\)\
\-\ infiltrating\\:\\ 0\\.14242921132233166\ \(0\)\
\-\ hemispheres\\:\\ 0\\.14097445858399393\ \(0\)\
\-\ always\\:\\ 0\\.13705113201612826\ \(0\)\
\-\ 66\\:\\ 0\\.13615801427268853\ \(0\)\
\-\ cns\\:\\ 0\\.13557955200840513\ \(0\)\
\-\ expansile\\:\\ 0\\.13137185104052715\ \(0\)\
\-\ almost\\:\\ 0\\.13042029183853146\ \(0\)\
\-\ problems\\:\\ 0\\.12593612449785896\ \(0\)\
\-\ component\\:\\ 0\\.12441619568288366\ \(0\)\
\-\ glioma\\:\\ 0\\.12333300055098745\ \(0\)\
\-\ csf\\:\\ 0\\.11471891508288182\ \(0\)\
\-\ family\\:\\ 0\\.11421985509275098\ \(0\)\
\-\ change\\:\\ 0\\.11001568436192954\ \(0\)\
\-\ marked\\:\\ 0\\.10980706643965503\ \(0\)\
\-\ ventricle\\:\\ 0\\.1068671197622622\ \(0\)\
\-\ grade\\:\\ 0\\.10439932367552701\ \(0\)\
\-\ chemotherapy\\:\\ 0\\.10308964599480427\ \(0\)\
\-\ involving\\:\\ 0\\.10169258069677461\ \(0\)\
\-\ or\\:\\ 0\\.10101326984207899\ \(0\)\
\-\ cerebral\\:\\ 0\\.10058422368045797\ \(0\)\
\-\ radiation\\:\\ 0\\.09621042085681532\ \(0\)\
\-\ past\\:\\ 0\\.09450322363643995\ \(0\)\
\-\ frontal\\:\\ 0\\.09344376369605994\ \(0\)\
\-\ abscess\\:\\ 0\\.09322623037163869\ \(0\)\
\-\ enhancing\\:\\ 0\\.09094858401811924\ \(0\)\
\-\ negative\\:\\ 0\\.08988189958678146\ \(0\)\
\-\ primary\\:\\ 0\\.08927197883761313\ \(0\)\
\-\ the\\:\\ 0\\.0869079010896237\ \(0\)\
\-\ months\\:\\ 0\\.08450834293612408\ \(0\)\
\-\ lesions\\:\\ 0\\.08338033362886435\ \(0\)\
\-\ who\\:\\ 0\\.08212455596559531\ \(0\)\
\-\ both\\:\\ 0\\.08096125900104932\ \(0\)\
\-\ over\\:\\ 0\\.08072821785932283\ \(0\)\
\-\ metastatic\\:\\ 0\\.07962569860825675\ \(0\)\
\-\ follow\\:\\ 0\\.07826632853253021\ \(0\)\
\-\ into\\:\\ 0\\.07717686662788958\ \(0\)\
\-\ noted\\:\\ 0\\.07697589693378461\ \(0\)\
\-\ woman\\:\\ 0\\.07561186254238011\ \(0\)\
\-\ in\\:\\ 0\\.07223371503743639\ \(0\)\
\-\ lateral\\:\\ 0\\.07205121210201858\ \(0\)\
\-\ disease\\:\\ 0\\.060942731380558515\ \(0\)\
\-\ there\\:\\ 0\\.05776792735542058\ \(0\)\
\-\ with\\:\\ 0\\.05685735415734376\ \(0\)\
\-\ mass\\:\\ 0\\.05545609004310002\ \(0\)\
\-\ are\\:\\ 0\\.05509040495882371\ \(0\)\
\-\ left\\:\\ 0\\.04952514108939422\ \(0\)\
\-\ year\\:\\ 0\\.04474259038689316\ \(0\)\
\-\ for\\:\\ 0\\.044003900467170724\ \(0\)\
\-\ old\\:\\ 0\\.04296837480343977\ \(0\)\
\-\ is\\:\\ 0\\.039759393752440676\ \(0\)\
\-\ to\\:\\ 0\\.03629550391381141\ \(0\)\
\-\ and\\:\\ 0\\.030000321796861372\ \(0\)\
\-\ of\\:\\ 0\\.02841170109403833\ \(0\)\
